journal
MENU ▼
Read by QxMD icon Read
search

Lancet

journal
https://www.readbyqxmd.com/read/28089472/department-of-error
#1
(no author information available yet)
No abstract text is available yet for this article.
January 12, 2017: Lancet
https://www.readbyqxmd.com/read/28089471/infantile-haemangioma
#2
REVIEW
Christine Léauté-Labrèze, John I Harper, Peter H Hoeger
With a prevalence of 4·5%, infantile haemangiomas are the most common benign tumours of infancy, arising in the first few weeks of life and exhibiting a characteristic sequence of growth and spontaneous involution. Most infantile haemangiomas do not require therapy. However, to identify at-risk haemangiomas, close follow-up is crucial in the first weeks of life; 80% of all haemangiomas reach their final size by 3 months of age. The main indications for treatment are life-threatening infantile haemangioma (causing heart failure or respiratory distress), tumours posing functional risks (eg, visual obstruction, amblyopia, or feeding difficulties), ulceration, and severe anatomic distortion, especially on the face...
January 12, 2017: Lancet
https://www.readbyqxmd.com/read/28088338/relation-between-resting-amygdalar-activity-and-cardiovascular-events-a-longitudinal-and-cohort-study
#3
Ahmed Tawakol, Amorina Ishai, Richard Ap Takx, Amparo L Figueroa, Abdelrahman Ali, Yannick Kaiser, Quynh A Truong, Chloe Je Solomon, Claudia Calcagno, Venkatesh Mani, Cheuk Y Tang, Willem Jm Mulder, James W Murrough, Udo Hoffmann, Matthias Nahrendorf, Lisa M Shin, Zahi A Fayad, Roger K Pitman
BACKGROUND: Emotional stress is associated with increased risk of cardiovascular disease. We imaged the amygdala, a brain region involved in stress, to determine whether its resting metabolic activity predicts risk of subsequent cardiovascular events. METHODS: Individuals aged 30 years or older without known cardiovascular disease or active cancer disorders, who underwent (18)F-fluorodexoyglucose PET/CT at Massachusetts General Hospital (Boston, MA, USA) between Jan 1, 2005, and Dec 31, 2008, were studied longitudinally...
January 12, 2017: Lancet
https://www.readbyqxmd.com/read/28088337/stressed-brain-stressed-heart
#4
Ilze Bot, Johan Kuiper
No abstract text is available yet for this article.
January 11, 2017: Lancet
https://www.readbyqxmd.com/read/28087069/safety-tolerability-and-antiviral-effect-of-rg-101-in-patients-with-chronic-hepatitis-c-a-phase-1b-double-blind-randomised-controlled-trial
#5
Meike H van der Ree, J Marleen de Vree, Femke Stelma, Sophie Willemse, Marc van der Valk, Svend Rietdijk, Richard Molenkamp, Janke Schinkel, Ad C van Nuenen, Ulrich Beuers, Salah Hadi, Marten Harbers, Eva van der Veer, Kai Liu, John Grundy, Amy K Patick, Adam Pavlicek, Jacqueline Blem, Michael Huang, Paul Grint, Steven Neben, Neil W Gibson, Neeltje A Kootstra, Hendrik W Reesink
BACKGROUND: miR-122 is an important host factor for hepatitis C virus (HCV) replication. The aim of this study was to assess the safety and tolerability, pharmacokinetics, and antiviral effect of a single dose of RG-101, a hepatocyte targeted N-acetylgalactosamine conjugated oligonucleotide that antagonises miR-122, in patients with chronic HCV infection with various genotypes. METHODS: In this randomised, double-blind, placebo-controlled, multicentre, phase 1B study, patients were randomly assigned to RG-101 or placebo (7:1)...
January 10, 2017: Lancet
https://www.readbyqxmd.com/read/28087068/clinical-development-of-hepatitis-c-virus-host-targeting-agents
#6
Mirjam B Zeisel, Thomas F Baumert
No abstract text is available yet for this article.
January 10, 2017: Lancet
https://www.readbyqxmd.com/read/28081952/thrombolytic-removal-of-intraventricular-haemorrhage-in-treatment-of-severe-stroke-results-of-the-randomised-multicentre-multiregion-placebo-controlled-clear-iii-trial
#7
Daniel F Hanley, Karen Lane, Nichol McBee, Wendy Ziai, Stanley Tuhrim, Kennedy R Lees, Jesse Dawson, Dheeraj Gandhi, Natalie Ullman, W Andrew Mould, Steven W Mayo, A David Mendelow, Barbara Gregson, Kenneth Butcher, Paul Vespa, David W Wright, Carlos S Kase, J Ricardo Carhuapoma, Penelope M Keyl, Marie Diener-West, John Muschelli, Joshua F Betz, Carol B Thompson, Elizabeth A Sugar, Gayane Yenokyan, Scott Janis, Sayona John, Sagi Harnof, George A Lopez, E Francois Aldrich, Mark R Harrigan, Safdar Ansari, Jack Jallo, Jean-Louis Caron, David LeDoux, Opeolu Adeoye, Mario Zuccarello, Harold P Adams, Michael Rosenblum, Richard E Thompson, Issam A Awad
BACKGROUND: Intraventricular haemorrhage is a subtype of intracerebral haemorrhage, with 50% mortality and serious disability for survivors. We aimed to test whether attempting to remove intraventricular haemorrhage with alteplase versus saline irrigation improved functional outcome. METHODS: In this randomised, double-blinded, placebo-controlled, multiregional trial (CLEAR III), participants with a routinely placed extraventricular drain, in the intensive care unit with stable, non-traumatic intracerebral haemorrhage volume less than 30 mL, intraventricular haemorrhage obstructing the 3rd or 4th ventricles, and no underlying pathology were adaptively randomly assigned (1:1), via a web-based system to receive up to 12 doses, 8 h apart of 1 mg of alteplase or 0·9% saline via the extraventricular drain...
January 9, 2017: Lancet
https://www.readbyqxmd.com/read/28081951/intracerebral-haemorrhage-no-good-treatment-but-treatment-helps
#8
Alejandro A Rabinstein
No abstract text is available yet for this article.
January 9, 2017: Lancet
https://www.readbyqxmd.com/read/28081950/department-of-error
#9
(no author information available yet)
No abstract text is available yet for this article.
January 9, 2017: Lancet
https://www.readbyqxmd.com/read/28077235/drivers-of-poor-medical-care
#10
REVIEW
Vikas Saini, Sandra Garcia-Armesto, David Klemperer, Valerie Paris, Adam G Elshaug, Shannon Brownlee, John P A Ioannidis, Elliott S Fisher
The global ubiquity of overuse and underuse of health-care resources and the gravity of resulting harms necessitate an investigation of drivers to inform potential solutions. We describe the network of influences that contribute to poor care and suggest that it is driven by factors that fall into three domains: money and finance; knowledge, bias, and uncertainty; and power and human relationships. In each domain the drivers operate at the global, national, regional, and individual level, and are modulated by the specific contexts within which they act...
January 6, 2017: Lancet
https://www.readbyqxmd.com/read/28077234/evidence-for-overuse-of-medical-services-around-the-world
#11
REVIEW
Shannon Brownlee, Kalipso Chalkidou, Jenny Doust, Adam G Elshaug, Paul Glasziou, Iona Heath, Somil Nagpal, Vikas Saini, Divya Srivastava, Kelsey Chalmers, Deborah Korenstein
Overuse, which is defined as the provision of medical services that are more likely to cause harm than good, is a pervasive problem. Direct measurement of overuse through documentation of delivery of inappropriate services is challenging given the difficulty of defining appropriate care for patients with individual preferences and needs; overuse can also be measured indirectly through examination of unwarranted geographical variations in prevalence of procedures and care intensity. Despite the challenges, the high prevalence of overuse is well documented in high-income countries across a wide range of services and is increasingly recognised in low-income countries...
January 6, 2017: Lancet
https://www.readbyqxmd.com/read/28077233/vikas-saini-leading-activist-in-the-right-care-alliance
#12
Richard Lane
No abstract text is available yet for this article.
January 6, 2017: Lancet
https://www.readbyqxmd.com/read/28077232/evidence-for-underuse-of-effective-medical-services-around-the-world
#13
REVIEW
Paul Glasziou, Sharon Straus, Shannon Brownlee, Lyndal Trevena, Leonila Dans, Gordon Guyatt, Adam G Elshaug, Robert Janett, Vikas Saini
Underuse-the failure to use effective and affordable medical interventions-is common and responsible for substantial suffering, disability, and loss of life worldwide. Underuse occurs at every point along the treatment continuum, from populations lacking access to health care to inadequate supply of medical resources and labour, slow or partial uptake of innovations, and patients not accessing or declining them. The extent of underuse for different interventions varies by country, and is documented in countries of high, middle, and low-income, and across different types of health-care systems, payment models, and health services...
January 6, 2017: Lancet
https://www.readbyqxmd.com/read/28077231/from-universal-health-coverage-to-right-care-for-health
#14
Sabine Kleinert, Richard Horton
No abstract text is available yet for this article.
January 6, 2017: Lancet
https://www.readbyqxmd.com/read/28077230/addressing-overuse-and-underuse-around-the-world
#15
Vikas Saini, Shannon Brownlee, Adam G Elshaug, Paul Glasziou, Iona Heath
No abstract text is available yet for this article.
January 6, 2017: Lancet
https://www.readbyqxmd.com/read/28077229/avoiding-overuse-the-next-quality-frontier
#16
Donald M Berwick
No abstract text is available yet for this article.
January 6, 2017: Lancet
https://www.readbyqxmd.com/read/28077228/levers-for-addressing-medical-underuse-and-overuse-achieving-high-value-health-care
#17
REVIEW
Adam G Elshaug, Meredith B Rosenthal, John N Lavis, Shannon Brownlee, Harald Schmidt, Somil Nagpal, Peter Littlejohns, Divya Srivastava, Sean Tunis, Vikas Saini
The preceding papers in this Series have outlined how underuse and overuse of health-care services occur within a complex system of health-care production, with a multiplicity of causes. Because poor care is ubiquitous and has considerable consequences for the health and wellbeing of billions of people around the world, remedying this problem is a morally and politically urgent task. Universal health coverage is a key step towards achieving the right care. Therefore, full consideration of potential levers of change must include an upstream perspective-ie, an understanding of the system-level factors that drive overuse and underuse, as well as the various incentives at work during a clinical encounter...
January 6, 2017: Lancet
https://www.readbyqxmd.com/read/28069280/a-new-therapeutic-advance-for-symptomatic-systemic-mastocytosis
#18
Michel Arock
No abstract text is available yet for this article.
January 6, 2017: Lancet
https://www.readbyqxmd.com/read/28069279/masitinib-for-treatment-of-severely-symptomatic-indolent-systemic-mastocytosis-a-randomised-placebo-controlled-phase-3-study
#19
Olivier Lortholary, Marie Olivia Chandesris, Cristina Bulai Livideanu, Carle Paul, Gérard Guillet, Ewa Jassem, Marek Niedoszytko, Stéphane Barete, Srdan Verstovsek, Clive Grattan, Gandhi Damaj, Danielle Canioni, Sylvie Fraitag, Ludovic Lhermitte, Sophie Georgin Lavialle, Laurent Frenzel, Lawrence B Afrin, Katia Hanssens, Julie Agopian, Raphael Gaillard, Jean-Pierre Kinet, Christian Auclair, Colin Mansfield, Alain Moussy, Patrice Dubreuil, Olivier Hermine
BACKGROUND: Indolent systemic mastocytosis, including the subvariant of smouldering systemic mastocytosis, is a lifelong condition associated with reduced quality of life. Masitinib inhibits KIT and LYN kinases that are involved in indolent systemic mastocytosis pathogenesis. We aimed to assess safety and efficacy of masitinib versus placebo in severely symptomatic patients who were unresponsive to optimal symptomatic treatments. METHODS: In this randomised, double-blind, placebo-controlled, phase 3 study, we enrolled adults (aged 18-75 years) with indolent or smouldering systemic mastocytosis, according to WHO classification or documented mastocytosis based on histological criteria, at 50 centres in 15 countries...
January 6, 2017: Lancet
https://www.readbyqxmd.com/read/28065560/sense-and-sensitivity-incompatible-patients-and-their-donors-in-kidney-transplantation
#20
Peter P Reese, Sumit Mohan
No abstract text is available yet for this article.
January 5, 2017: Lancet
journal
journal
20186
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"